Moderna (MRNA) Stock Forecast: Growth Prospects and What’s Next
Written by F, Fairy.fLast updated: 
Moderna, Inc. is a U.S. biotechnology company that develops vaccines and therapies using mRNA technology. It is listed on the NASDAQ under the ticker “MRNA.”
Moderna’s stock fell sharply after COVID-19 vaccine demand peaked. Then, in August 2026, shares surged on clinical trial results for a personalized mRNA cancer vaccine developed with Merck.
This article covers Moderna’s (MRNA) business, financial results, and stock price trends. It also explains why the stock has risen and fallen, what the future may hold, and analyst price targets.
| Table of Contents |
|
What Is Moderna (MRNA)?
Moderna, Inc. is a biotechnology company headquartered in Massachusetts, USA.
Moderna listed on the NASDAQ in December 2018 and trades under the ticker “MRNA.”
The company focuses on developing drugs and vaccines based on messenger RNA (mRNA) technology.
Moderna became globally known for its COVID-19 vaccine. Since then, it has expanded beyond infectious diseases into cancer and rare diseases.
Moderna (MRNA) Business Overview and Features
Moderna’s core strength is its R&D platform built around mRNA technology.
mRNA technology uses molecular instructions that tell cells to produce specific proteins. Moderna applies this technology to develop vaccines and therapies.
Moderna is expanding its research beyond infectious disease vaccines into oncology.
One of its most closely watched programs is intismeran autogene, a personalized mRNA cancer vaccine developed with Merck.
The therapy is designed to match each patient’s tumor. Moderna is developing it in combination with Merck’s immune checkpoint inhibitor Keytruda.
Moderna (MRNA) Latest Financial Results and Performance
Moderna’s full-year 2025 revenue came in at $1.9 billion, down from $3.2 billion in 2024.
Its full-year 2025 GAAP net loss was $2.8 billion, or a diluted loss of $7.26 per share.
Lower COVID-19 vaccine demand weighed heavily on results.
At the same time, Moderna has been cutting costs. In 2025, it delivered $2.2 billion in annual cost savings.
For 2026, Moderna maintained its plan to grow revenue by up to 10%.
Second-quarter 2026 revenue was about $100 million, with a GAAP net loss of $0.8 billion and a GAAP loss of $1.97 per share.
Moderna expects its cash and cash equivalents balance to end 2026 between $4.7 billion and $5.2 billion.
Moderna (MRNA) Stock Price Trends
Moderna’s stock surged in 2021, when COVID-19 vaccine demand was at its peak.
After that, the shares trended lower as vaccine demand faded.
On November 21, 2025, the stock hit a 52-week low of $22.28.
In 2026, however, the stock regained upward momentum.
On August 19, 2026, Moderna closed at $174.38 after an intraday high of $176.66.
The next day, August 20, the stock fell sharply. By August 21, it had dropped to $133.32.
This price action highlights how volatile Moderna’s stock has become.
Source: Yahoo! Finance
Given the sharp swings in Moderna’s stock, it is difficult to judge whether the current price is cheap or expensive based on price alone.
Why Moderna (MRNA) Stock Recently Surged
Cancer Vaccine Clinical Trial Results
The biggest driver of Moderna’s recent surge was the clinical trial data for its cancer vaccine developed with Merck.
On August 19, 2026, Moderna and Merck announced that intismeran autogene met primary endpoints in a Phase 3 trial.
The study enrolled melanoma patients at high risk of recurrence or metastasis.
The results renewed interest in using mRNA technology to treat cancer.
Source: Reuters
Renewed Expectations for the mRNA Business
The results signaled that Moderna could move beyond its reliance on COVID-19 vaccines.
Moderna is developing multiple mRNA medicines, including several in oncology.
Investors viewed the clinical trial success as a potential medium- to long-term growth catalyst.
Moderna’s stock rose sharply on August 19, 2026.
Source: Financial Times
Short Covering Also Added to the Rally
Short covering also played a role in Moderna’s stock surge.
According to Reuters, short interest reached 13.5% of free float.
When a stock jumps, short sellers often buy back shares to cap their losses.
That buying pressure may have accelerated the rally.
Source: Reuters
Moderna (MRNA) Future Outlook and Growth Potential
Expansion into Cancer
Cancer is a key part of Moderna’s long-term growth story.
The latest trial results highlighted mRNA’s potential beyond infectious disease.
Moderna is also researching mRNA treatments for other types of cancer.
Still, positive data in one trial does not mean every cancer program will succeed.
Investors will need to watch detailed clinical data and regulatory decisions.
Diversifying Revenue with New Products
Moderna is working to build revenue sources beyond COVID-19 vaccines.
In August 2026, the U.S. FDA approved mFLUSIVA, Moderna’s mRNA seasonal flu vaccine.
It is the first mRNA-based seasonal influenza vaccine approved in the U.S.
Moderna also plans to develop combination vaccines targeting flu and COVID-19.
Path to Cash Break-Even by 2028
Moderna is aiming to improve profitability through cost cuts and new product launches.
The company targets a cash-based break-even point by 2028.
Whether it reaches that target could also affect the stock’s medium- to long-term valuation.
That said, clinical trials and regulatory approvals carry significant uncertainty.
When evaluating Moderna’s prospects, investors should track R&D progress as well as revenue.
Moderna (MRNA) Stock Price Forecast
Analyst Target Prices
Analyst price targets for Moderna shifted sharply around the August 19, 2026 surge.
On August 20, Morgan Stanley raised its target from $39 to $89 while keeping an “Equalweight” rating.
Bank of America lifted its target to $170, and RBC Capital raised its target to $130.
Still, targets vary widely across institutions.
Source: Investing.com
What Could Push Moderna’s Stock Higher
Further upside will likely depend on progress in Moderna’s cancer pipeline.
If intismeran autogene advances through development and reaches approval, it could become a meaningful revenue source.
Broader adoption of products such as the flu vaccine could also support financial results.
In addition, sustained cost discipline and progress toward cash break-even in 2028 could improve investor sentiment.
What Could Push Moderna’s Stock Lower
There are also meaningful downside risks.
If future trials miss expectations, the market’s current optimism could fade quickly.
After the sharp rally, the stock pulled back on profit-taking and valuation concerns.
Moderna is also still loss-making, with a GAAP net loss of roughly $0.8 billion in the second quarter of 2026.
So, when assessing Moderna’s stock, investors should look beyond expectations and assess whether profitability is actually improving.
Source: Moderna Quarterly Results
Conclusion: Moderna Stock Price Outlook
Moderna’s stock fell over a long stretch as COVID-19 vaccine demand weakened.
In 2026, however, expectations for mRNA-based cancer treatment have revived.
The Phase 3 results for intismeran autogene, developed with Merck, became a major catalyst.
At the same time, the stock’s sharp surge and rapid pullback show how volatile it has become.
Going forward, watch cancer clinical data, new product sales, and profitability trends.
When assessing Moderna’s future, don’t rely only on analyst targets — review the company’s financial results and pipeline progress.
In addition, Moderna pays no dividend, so it is not suited to income-focused investors.
How much the stock rises or falls from here will likely depend on how quickly mRNA technology can be commercialized.
BTCC’s homepage will continue to bring you the latest news affecting Moderna’s stock, key regulatory updates, and broader stock market trends. We hope you find it useful.
Related Articles
Why Is HYPE Surging? What Does Trump’s Support for Hyperliquid’s U.S. Entry Mean?
Bitway (BTW) Up 500% in One Month: What Is It and Why Is It Surging?
What Is United States Oil Holdings (USOH)? Is It Legit or a Scam?
BTCC VIP Complete Guide: Levels, Fees, Benefits & Comparison
